Why the study?
Does bone marrow-derived stem cell therapy improve cardiac repair in the event of myocardial injury?
Does bone marrow-derived stem cell therapy improve cardiac repair in the event of myocardial injury?
This review summarizes the rationale and emerging evidence for using bone marrow-derived stem cells to supplement intrinsic cardiac repair mechanisms following myocardial injury.
Answers are grounded in this paper and cite their sources.
Leaves open clinical efficacy of bone marrow stem cells post-MI; supports targeted trials to test repair augmentation.
Cardiomyocytes respond to physiological or pathological stress only by hypertrophy and not by an increase in the number of functioning cardiomyocytes. However, recent evidence suggests that adult cardiomyocytes have the ability, albeit limited, to divide to compensate for the cardiomyocyte loss in the event of myocardial injury. Similarly, the presence of stem cells in the myocardium is a good omen. Their activation to participate in the repair process is, however, hindered by some as-yet-undetermined biological impediments. The rationale behind the use of adult stem cell transplantation is to supplement the inadequacies of the intrinsic repair mechanism of the heart and compensate for the cardiomyocyte loss in the event of injury. Various cell types including embryonic, fetal, and adult cardiomyocytes, smooth muscle cells, and stable cell lines have been used to augment the declining cardiomyocyte number and cardiac function. More recently, the focus has been shifted to the use of autologous skeletal myoblasts and bone marrow-derived stem cells. This review is a synopsis of some interesting aspects of the fast-emerging field of bone marrow-derived stem cell therapy for cardiac repair.
No takes yet. Share an insight, caveat, or question.
Haider et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: